Magnus Lindskog

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Docent och överläkare i urologisk onkologi. Processledare för Njurcancer i Region Stockholm-Gotland. Jag kombinerar klinisk verksamhet med patientnära forskning med fokus på två huvudsakliga frågeställningar: (1) Hur påverkar olika onkologiska och kirurgiska behandlingar överlevnad vid njurcancer som hunnit sprida sig eller har en hög risk för återfall? (2) Vilka medicinska åtgärder är meningsfulla för cancerpatienter i sent palliativt skede?

Artiklar

Article: JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2025;70(1):38-45
Bronchoscopic Intervention Reduces Dyspnea in Severely Symptomatic Patients With Central Malignant Airway Obstruction.
Svensson M; Palm A; Westöö N; Lindskog M
Article: CANCER IMAGING. 2025;25(1):30
The value of whole-body MRI instead of only brain MRI in addition to 18 F-FDG PET/CT in the staging of advanced non-small-cell lung cancer
Holmstrand H; Lindskog M; Sundin A; Hansen T
Article: BMC PALLIATIVE CARE. 2024;23(1):178
Fluid therapy is associated with lower care quality and higher symptom burden during last days of life of patients with cancer - a population-based register study
Lindskog M; Mogensen H; Tavelin B; Eknert J; Lundstrom S; Strang P
Article: LANCET ONCOLOGY. 2024;25(5):e193-e204
Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology.
Marvaso G; Jereczek-Fossa BA; Zaffaroni M; Vincini MG; Corrao G; Andratschke N; Balagamwala EH; Bedke J; Blanck O; Capitanio U; Correa RJM; De Meerleer G; Franzese C; Gaeta A; Gandini S; Garibaldi C; Gerszten PC; Gillessen S; Grubb WR; Guckenberger M; Hannan R; Jhaveri PM; Josipovic M; Kerkmeijer LGW; Lehrer EJ; Lindskog M; Louie AV; Nguyen Q-N; Ost P; Palma DA; Procopio G; Rossi M; Staehler M; Tree AC; Tsang YM; Van As N; Zaorsky NG; Zilli T; Pasquier D; Siva S
Article: BMC PHARMACOLOGY & TOXICOLOGY. 2024;25(1):25
Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
Selvin T; Berglund M; Lenhammar L; Lindskog M; Jarvius M; Larsson R; Nygren P; Fryknaes M; Andersson CR
Article: CASE REPORTS IN ONCOLOGY. 2024;17(1):1124-1130
Immunotherapy and Tyrosine Kinase Inhibitor as a Bridge to Surgery for Clear Cell Renal Cell Carcinoma Metastases to the Thyroid: A Case Report and Literature Review
Branstrom R; Zedenius J; Shabo I; Lindskog M; Juhlin CC
Article: JAMA NETWORK OPEN. 2023;6(3):e234149
Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial
Werlenius K; Kinhult S; Solheim TS; Magelssen H; Loefgren D; Mudaisi M; Hylin S; Bartek JJ; Strandeus M; Lindskog M; Rashid HB; Carstam L; Gulati S; Solheim O; Bartek J; Salvesen O; Jakola AS
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;24(1):193
Matched Analyses of Brain Metastases versus Primary Non-Small Cell Lung Cancer Reveal a Unique microRNA Signature
Tsakonas G; Koulouris A; Kazmierczak D; Botling J; Ortiz-Villalon C; Nord H; Lindskog M; Sandelin M; Micke P; Hydbring P; Ekman S
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2022;56(5-6):383-390
Surgical waiting times and all-cause mortality in patients with non-metastatic renal cell carcinoma
Rosenblad AK; Sundqvist P; Harmenberg U; Hellstrom M; Hofmann F; Kjellman A; Dahlin B-IK; Lindblad P; Lindskog M; Lundstam S; Ljungberg B
Article: BMC PALLIATIVE CARE. 2022;21(1):133
Acute healthcare utilization in end-of-life among Swedish brain tumor patients - a population based register study
Lindskog M; Schultz T; Strang P
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;40:38-45
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
Lindskog M; Laurell A; Kjellman A; Melichar B; Rey PM; Zielinski H; Villacampa F; Bigot P; Zoltan B; Parikh O; Alba DV; Jellvert D; Flasko T; Gallardo E; Caparros MJR; Purkalne G; Suenaert P; Karlsson-Parra A; Ljungberg B
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;39:22-28
Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease-A National Register Study
Almdalal T; Sundqvist P; Harmenberg U; Hellstrom M; Lindskog M; Lindblad P; Lundstam S; Ljungberg B
Article: ACTA NEUROCHIRURGICA. 2021;163(2):333-342
Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery
Stenman M; Benmakhlouf H; Wersall P; Johnstone P; Hatiboglu MA; Mayer-da-Silva J; Harmenberg U; Lindskog M; Sinclair G
Article: EUROPEAN JOURNAL OF CANCER. 2020;132:24-34
An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer
Tsakonas G; Lewensohn R; Botling J; Ortiz-Villalon C; Micke P; Friesland S; Nord H; Lindskog M; Sandelin M; Hydbring P; Ekman S
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(5_suppl):11
A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma.
Lindskog M; Laurell A; Kjellman A; Melichar B; Niezabitowski J; Maroto P; Zieliński H; Villacampa F; Bigot P; Bajory Z; Parikh O; Vazquez Alba D; Jellvert A; Flasko T; Gallardo Diaz E; Ribal MJ; Purkalne G; Suenaert P; Karlsson-Parra A; Ljungberg B
Article: ACTA ONCOLOGICA. 2019;58(4):432-438
Cancer patients hospitalised in the last week of life risk insufficient care quality - a population-based study from the Swedish Register of Palliative Care
Elmstedt S; Mogensen H; Hallmans D-E; Tavelin B; Lundstrom S; Lindskog M
Article: ACTA ONCOLOGICA. 2019;58(3):306-312
Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres
Stenman M; Staehler M; Szabados B; Sandstrom P; Laurell A; Lindskog M; Harmenberg U
Article: CANCER MANAGEMENT AND RESEARCH. 2019;11:1289-1297
Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis
Redig J; Dalen J; Harmenberg U; Lindskog M; Ljungberg B; Lundstam S; Sandin R; Wahlgren T; Akerborg O; Jakobsson M
Article: RADIOTHERAPY AND ONCOLOGY. 2018;127(3):501-506
Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014
Stenman M; Sinclair G; Paavola P; Wersall P; Harmenberg U; Lindskog M
Article: F1000RESEARCH. 2018;7:1797
Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trial.
Jakola AS; Werlenius K; Mudaisi M; Hylin S; Kinhult S; Bartek J; Salvesen Ø; Carlsen SM; Strandéus M; Lindskog M; Löfgren D; Rydenhag B; Carstam L; Gulati S; Solheim O; Bartek J; Solheim T
Article: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2017;35(9):541.e15-541.e22
Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations
Lindskog M; Wahlgren T; Sandin R; Kowalski J; Jakobsson M; Lundstam S; Ljungberg B; Harmenberg U
Article: BMC MEDICAL ETHICS. 2016;17(1):30
Heed or disregard a cancer patient's critical blogging? An experimental study of two different framing strategies
Lynoe N; NattochDag S; Lindskog M; Juth N
Article: EUROPEAN JOURNAL OF CANCER. 2015;51(10):1331-1339
Old age as risk indicator for poor end-of-life care quality - A population-based study of cancer deaths from the Swedish Register of Palliative Care
Lindskog M; Tavelin B; Lundstrom S
Article: MEDICAL ONCOLOGY. 2014;31(3):841
Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma
Stenman M; Laurell A; Lindskog M
Article: BONE MARROW TRANSPLANTATION. 2013;48(6):843-848
Omega-3 from fish oil augments GVHD through the enhancement of chemotherapy conditioning regimen and selective FoxP3 depletion
Al Hashmi S; Sadeghi B; Hassan Z; Abedi-Valugerdi M; Lindskog M; Hassan M
Article: EUROPEAN JOURNAL OF CANCER. 2013;49(1):115-120
Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.
Sörenson S; Fohlin H; Lindgren A; Lindskog M; Bergman B; Sederholm C; Ek L; Lamberg K; Clinchy B
Article: INTERNATIONAL JOURNAL OF CANCER. 2011;128(7):1703-1711
Omega-3 fatty acid supplementation delays the progression of neuroblastoma in vivo
Gleissman H; Segerstrom L; Hamberg M; Ponthan F; Lindskog M; Johnsen JI; Kogner P
Article: LEUKEMIA & LYMPHOMA. 2010;51(11):2092-2097
Fish oil delays lymphoma progression in the TLL mouse
Johansson A-S; Noren-Nystrom U; Larefalk A; Holmberg D; Lindskog M
Article: FASEB JOURNAL. 2010;24(3):906-915
Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates
Gleissman H; Yang R; Martinod K; Lindskog M; Serhan CN; Johnsen JI; Kogner P
Article: JOURNAL OF NATURAL PRODUCTS. 2009;72(11):1969-1974
Cytotoxic Effects of Cardiac Glycosides in Colon Cancer Cells, Alone and in Combination with Standard Chemotherapeutic Drugs
Felth J; Rickardson L; Rosen J; Wickstrom M; Fryknas M; Lindskog M; Bohlin L; Gullbo J
Article: LEUKEMIA & LYMPHOMA. 2009;50(7):1198-1203
Lymphoblastic T-cell lymphoma in mice is unaffected by Celecoxib as single agent or in combination with cyclophosphamide
Johansson A-S; Pawelzik S-C; Larefalk A; Jakobsson P-J; Holmberg D; Lindskog M
Article: INTERNATIONAL JOURNAL OF CANCER. 2009;124(5):1227-1234
Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo
Paimberg E; Johnsen JI; Paulsson J; Gleissman H; Wickstrom M; Edgren M; Ostman A; Kogner P; Lindskog M
Journal article: BLOOD. 2008;112(11):4602
The Effect of Omega-3 as a Dietary Supplement in a Mouse Model of Stem Cell Transplantation (SCT)
Al-Hashmi SA; Sadeghi B; Hassan Z; Lindskog M; Hassan M
Article: MOLECULAR CANCER THERAPEUTICS. 2007;6(9):2409-2417
The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo
Wickstrom M; Johnsen JI; Ponthan F; Segerstrom L; Sveinbjornsson B; Lindskog M; Lovborg H; Viktorsson K; Lewensohn R; Kogner P; Larsson R; Gullbo J
Article: INTERNATIONAL JOURNAL OF CANCER. 2006;118(10):2584-2593
Neuroblastoma cell death in response to docosahexaenoic acid: Sensitization to chemotherapy and arsenic-induced oxidative stress
Lindskog M; Gleissman H; Ponthan F; Castro J; Kogner P; Johnsen JI
Article: CANCER RESEARCH. 2004;64(20):7210-7215
Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo
Johnsen JI; Lindskog M; Ponthan F; Pettersen I; Elfman L; Orrego A; Sveinbjörnsson B; Kogner P
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2004;96(19):1457-1466
Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma
Lindskog M; Spenger C; Jarvet J; Gräslund A; Kogner P
Article: ONCOLOGY REPORTS. 2003;10(5):1587-1592
Evaluation of anti-tumour effects of oral fenretinide (4-HPR) in rats with human neuroblastoma xenografts
Ponthan F; Lindskog M; Karnehed N; Castro J; Kogner P
Article: BRITISH JOURNAL OF CANCER. 2003;88(3):478-485
Noninvasive estimation of tumour viability in a xenograft model of human neuroblastoma with proton magnetic resonance spectroscopy (¹H MRS)
Lindskog M; Kogner P; Ponthan F; Schweinhardt P; Sandstedt B; Heiden T; Helms G; Spenger C
Article: CLINICAL CHEMISTRY. 2003;49(1):104-112
Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastorna cells in blood and bone marrow
Träger C; Kogner P; Lindskog M; Ponthan F; Kullman A; Kågedal B
Visa fler

Alla övriga publikationer

Letter: WORLD JOURNAL OF UROLOGY. 2024;42(1):621
Reply to Letter to the Editor about "Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis" by Qiang et al
Rosenblad AK; Hashim BM; Lindblad P; Ljungberg B
Conference publication: SCANDINAVIAN JOURNAL OF UROLOGY. 2023;58:31-32
Neoadjuvant effects in a randomized phase 2 study with a cell-based immune primer plus sunitinib versus sunitinib alone in patients with metastatic Renal Cell Carcinoma
Ljungberg B; Lindskog M; Karlsson-Parra A
Other: SURGICAL NEUROLOGY INTERNATIONAL. 2020;11:21
Adaptive radiosurgery based on two simultaneous dose prescriptions in the management of large renal cell carcinoma brain metastases in critical areas: Towards customization.
Sinclair G; Stenman M; Benmakhlouf H; Johnstone P; Wersäll P; Lindskog M; Hatiboglu MA; Harmenberg U
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(5)
A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma
Lindskog M; Laurell A; Kjellman A; Melichar B; Niezabitowski J; Maroto P; Zielinski H; Villacampa F; Bigot P; Bajory Z; Parikh O; Alba DV; Jellvert A; Flasko T; Diaz EG; Ribal MJ; Purkalne G; Suenaert P; Karlsson-Parra A; Ljungberg B
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(2):535
Metastatic papillary renal cell carcinoma: A retrospective study from two large academic centers in Sweden.
Stenman M; Nearchou AD; Sandstrom P; Lindskog M; Harmenberg U
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2015;33(7):413
Overall survival (OS) in Swedish RCC patients treated 2000-2012: Update of the RENCOMP study.
Lindskog M; Wahlgren T; Sandin R; Kowalski J; Jakobsson M; Lundstam S; Ljungberg B; Harmenberg U
Review: CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE. 2014;8(4):378-382
Glycaemic control in end-of-life care: fundamental or futile?
Lindskog M; Karvestedt L; Furst CJ
Conference publication: BLOOD. 2012;120(21):4671
Omega-3 From Fish Oil Augments Gvhd Through the Enhancement of Chemotherapy Conditioning Regimen and Selective Foxp3 Depletion
Al Hashmi S; Sadeghi B; Hassan Z; Lindskog M; Hassan M
Conference publication: HAEMATOLOGICA. 2009;94:472
THE EFFECT OF OMEGA-3 AS A DIETARY SUPPLEMENT IN A MOUSE MODEL OF STEM CELL TRANSPLANTATION (SCT)
Al-Hashmi A; Sadeghi B; Hassan Z; Lindskog M; Hassan M
Conference publication: PEDIATRIC BLOOD & CANCER. 2009;53(5):807
OMEGA-3 FATTY ACIDS IN CHILDHOOD CANCER: ELUCIDATION OF THE DOCOSAHEXAENOIC ACID METABOLIC PATHWAY IN NEUROBLASTOMA AND DEFINITION OF CYTOTOXIC INTERMEDIATES
Kogner P; Gleissman H; Serhan CN; Hamberg M; Segerstrom L; Lindskog M; Johnsen JI
Conference publication: CANCER RESEARCH. 2009;69
Omega-3 fatty acids in cancer: Elucidation of the docosahexaenoic acid metabolic pathway in neuroblastoma cells, and definition of cytotoxic intermediates
Gleissman H; Serhan C; Hamberg M; Lindskog M; Kogner P; Johnsen J
Conference publication: CANCER RESEARCH. 2009;69
Novel tyrosine kinase inhibitors are effective in in vitro models of high risk neuroblastoma
Palmberg E; Rickardson L; Johnsen JI; Kogner P; Lindskog M
Conference publication: CANCER RESEARCH. 2006;66(8)
Omega-3 docosahexaenoic acid inhibits neuroblastoma cell growth in vivo
Gleissman H; Lindskog M; Ponthan F; Elfman L; Johnsen JI; Kogner P
Review: CANCER LETTERS. 2005;228(1-2):195-201
NSAIDs in neuroblastoma therapy
Johnsen JI; Lindskog M; Ponthan F; Pettersen I; Elfman L; Orrego A; Sveinbjörnsson B; Kogner P
Review: CANCER LETTERS. 2005;228(1-2):247-255
Proton magnetic resonance spectroscopy in neuroblastoma:: Current status, prospects and limitations
Lindskog M; Spenger C; Klason T; Jarvet J; Gräslund A; Johnsen JI; Ponthan F; Douglas L; Nordell B; Kogner P
Doctoral thesis: 2004
Tumor lipid status and the responses to therapy in neuroblastoma : with emphasis on treatment monitoring by proton magnetic resonance spectroscopy
Lindskog M
Published conference paper: SPECTROSCOPY. 2004;18(2):123-132
Monitoring intracellular metabolites in neuroblastoma with 1H NMR spectroscopy: effects of growth factor withdrawal and modulation of lipid metabolism
Lindskog M; Jarvet J; Graslund A; Kogner P

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2025-2028

Examina och utbildning

Läkarexamen, Karolinska Institutet, 2006
MEDICINE DOKTORSEXAMEN, Institutionen för kvinnors och barns hälsa, Karolinska Institutet, 2004

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI